On October 7, Novoprotein disclosed that, in 2025, the revenue generated from its RNA vaccine-related products constituted 11.38% of its total product revenue, indicating a comparatively modest share (refer to the 2025 annual report for further specifics). The company's AI-empowered high-throughput wet lab experiments and data package services are currently in the embryonic stages of market penetration. As of the first half of 2026, the revenue derived from these associated ventures accounted for a mere fraction—less than 2%—of the company's aggregate operating revenue. Considering that the integration of AI in drug research and development is still in its formative years and confronts hurdles such as swift technological advancements, protracted industry validation processes, and obstacles in commercialization, there exists considerable ambiguity surrounding the company's prospective revenue and profitability in this domain.